APR 02, 2018 08:37 PM PDT

'Fish Hooks' Speed Up Drug Discovery

WRITTEN BY: Nouran Amin

 

DNA-encoded chemical library (DECL), containing about 35 million different drugs, is a new screening method developed to speed up drug discovery.

The collection of drug candidates consist of basic ring-shaped structures based on the work of Manfred Mutter from the University of Lausanne where three different molecules were attached to one side of each ring structure. “Together, they form a kind of highly-specific fish hook that can bind onto a protein if its form perfectly matches the protein’s structure,” says lead researcher Jörg Scheuermann of ETH Zurich. Now, DECL researchers use the library for all kinds of “fish hooks” creating various combinations.

Investigators encoded the blueprint of these molecules in short DNA sequences where the genetic material was bound to the reverse of the basic structure producing an artificial piece of DNA that serves as a “barcode”. Investigators can use such barcode to identify each fish hook individually. This can allow the ability to detect a target protein caught by one of the “fish hooks”. So, researchers placed all 35 million compounds a reaction vessel containing the protein of interest. After a period of time ,they washed the chemical collection away hoping that those drugs that failed to bind to the carrier protein were discarded, and those that succeeded in binding remained in the vessel. Those drugs that were not washed away were identified using DNA barcodes. The identifications of those remaining in the sample can allow researchers to further potential testing and narrow down their options until a match is made.

Image via Phys.org

The development of DECLs was in works for years. The basics of DECLs which are the essential foundations of DNA-encoding were first described in the early 1990s by Scripps researchers Richard Lerenr and Sidney Brenner but was not put into practice until a decade later when researchers at Harvard University worked on the idea and later presented the first DNA-encoding chemical collection.

The progress of DECL has been crucial in the pharmaceutical industry due to its inexpensiveness and efficacy. “The design of our DECL is based on the fact that we wanted to generate a new molecule form that would be functionally equivalent to an antibody reduced to its minimum size, and therefore accessible via chemical synthesis,” explains Scheuermann. “By using molecules that possess three or more chemical hooks, we come closer to antigen-antibody interactions.”

A proposed treatment option involves linking a particular protein known as a cytotoxin to a small-molecule drug conjugate, protein binder. This approach allows the cytotoxin to recognize a foreign invader or tumor cell, bind to it, and release the toxic activity in a localized concentration, leading to tumor cellular death. This method was previously used with antibodies as antibody-drug conjugates (ADC).“However, as antibodies are relatively large, they were not able to penetrate tumor tissue well; small molecules should be able to accomplish this better,” explains Scheuermann.

Sources: Nature Chemistry

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 15, 2018
Drug Discovery
MAY 15, 2018
A Cure for The Common Cold?
Treating the common cold has never been simple and finding effective options has baffled scientists for centuries. The common cold is caused, for the most ...
JUN 20, 2018
Drug Discovery
JUN 20, 2018
The Role of Estrogen Therapy in Gut Bacteria
A recent research study on mouse models found that periodic treatment of estrogen and bazeedoxifene has affected estrogen metabolism and altered the microb...
JUL 04, 2018
Drug Discovery
JUL 04, 2018
Increased Dose of Drug 'Rifampin' Effective in Eliminating Tuberculosis Bacterium
According to a randomized controlled trial, a TB drug by the name ‘Rifampin’ was seen to effectively kill TB bacteria in sputum cultures when a...
JUL 11, 2018
Drug Discovery
JUL 11, 2018
Blood Pressure Medication 'Verapamil' Stimulates Insulin Production
A common blood pressure medication, verapamil, may improve outcomes for patients with Type 1 diabetes. According to researchers at the University of Alabam...
AUG 08, 2018
Drug Discovery
AUG 08, 2018
Injection Improves Corneal Transplant Outcomes
The common form of tissue transplant is the corneal transplant. Corneal transplantation is performed to correct visual loss that has occurred when the corn...
AUG 14, 2018
Cancer
AUG 14, 2018
New Drug for Refractory Cutaneous T-cell Lymphoma
Mogamulizumab was approved by the FDA this month after a very successful Phase III clinical trial demonstrating its effectiveness in treating patients with challenging CTCL....
Loading Comments...